rss
Eur J Hosp Pharm 20:A43-A44 doi:10.1136/ejhpharm-2013-000276.121
  • General and risk management, patient safety

GRP-121 Multidisciplinary Monitoring of Psychiatric Morbidity of HCV-Infected Patients Treated with Interferon and Ribavirin

  1. MQ Gorgas1
  1. 1Corporación Sanitaria Parc Tauli, Pharmacy, Sabadell, Spain
  2. 2Corporación Sanitaria Parc Tauli, Clinic Pharmacology, Sabadell, Spain
  3. 3Corporación Sanitaria Parc Tauli, Digestive Diseases, Sabadell, Spain
  4. 4Corporación Sanitaria Parc Tauli, Mental Illness, Sabadell, Spain

Abstract

Background Treatment of hepatitis C virus (HCV) infection with pegylated interferon and ribavirin may induce psychiatric disorders, which may result in poor adherence and response to antiviral treatment.

Purpose We aimed to describe the incidence of neuropsychiatric disorders in a cohort of HCV-infected patients treated with interferon and ribavirin, and their impact on treatment adherence and viral response rate (SVR).

Materials and Methods Data from a cohort of HCV patients who visited an outpatient pharmacy service (OPS) included all adult patients mono-infected with HCV who had completed treatment in 2010. Monitoring of neuropsychiatric disorders was assessed at weeks 0, 4, 12, 24, 48, and 72 through the self-administered questionnaires Hospital Anxiety and Depression Scale (HADS) and General Health Questionnaire (Goldberg). Adherence to treatment was assessed by counting drugs dispensed and patient reporting. Virological response was determined by the physician according to standard criteria.

Results Of the 76 patients included, 19 (25%) had a pre-existing psychiatric disorder, mostly depression and anxiety. The incidence of medically-confirmed neuropsychiatric disorders was 33% (n = 25), with a peak of abnormal results in the tests in week 12. Patients with and without pathological scores did not differ in baseline characteristics, except for pre-existing psychiatric disorder [60.0% vs. 7.8%, respectively (p < 0.001). Antidepressants and/or anxiolytics were prescribed to 48% of patients with medically confirmed disorders (n = 12). Overall, 43% of patients achieved an SVR. Strict adherence (96% vs. 90%; p = NS) and SVR (39% vs. 52%; p = NS) were similar in patients with or without medically confirmed disorders.

Conclusions Patients often develop neuropsychiatric disorders during interferon therapy. Neuropsychiatric side effects had a non-significant effect on adherence to treatment and attainment of SVR. Multidisciplinary monitoring provided during the treatment of hepatitis C can contribute to early detection and management of neuropsychiatric disorders and to improve integrated patient care.

No conflict of interest.

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article